Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 1 1

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 69Breast 6Genitourinary 2Gastrointestinal 2Sarcoma 1Other hematologic neoplasm 1Lymphoid 1Classical hematology 1

Conditions

Prostatic Neoplasms 15Prostatic Neoplasms, Castration-Resistant 2Pancreatic Neoplasms 2Ovarian Neoplasms 2Head and Neck Neoplasms 2Carcinoma, Transitional Cell 2Carcinoma, Renal Cell 2Breast Neoplasms 2Uveal Melanoma 1Urothelial Cancer 1Urologic Neoplasms 1Urogenital Neoplasms 1Urinary Bladder Neoplasms 1Sarcoma 1Prostatic Diseases 1Prostate Carcinoma Metastatic to the Bone 1Prostate Adenocarcinoma 1Penile Neoplasms 1Ovarian Diseases 1Neoplasms 1Neoplasm Metastasis 1Metastatic Hormone-sensitive Prostate Cancer (mHSPC) 1Metastatic Castration-sensitive Prostate Cancer 1Metastatic Castration-resistant Prostate Cancer (mCRPC) 1Metastatic Castration-resistant Prostate Cancer 1Mesothelioma 1Melanoma 1Lung Neoplasms 1Leukemia, Prolymphocytic, T-Cell 1Leukemia, Lymphocytic, Chronic, B-Cell 1

Interventions

pembrolizumab 36Carboplatin 28Paclitaxel 23Filgrastim 17Nivolumab 14Gemcitabine 14Cyclophosphamide 14Ifosfamide 13Cisplatin 13Docetaxel 12Specimen Handling 11Etoposide 11olaparib 9Peripheral Blood Stem Cell Transplantation 9Magnetic Resonance Spectroscopy 8fludarabine 6Temozolomide 6Ipilimumab 6Fluorouracil 6Biopsy 6Albumin-Bound Paclitaxel 6rucaparib 5avelumab 5atezolizumab 5Trastuzumab 5Thiotepa 5Taxes 5Standard of Care 5palbociclib 4durvalumab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Ovarian Neoplasms × niraparib × Genitourinary × Clear all
NCT05238831 2024-01-23

SMMART Adaptive Clinical Treatment (ACT) Trial

OHSU Knight Cancer Institute

Phase EARLY_PHASE1 Withdrawn
BreastGastrointestinalGenitourinaryGynecologicSarcoma

Breast Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma

NCT00749502 2013-07-25

A Study of MK4827 in Participants With Advanced Solid Tumors or Hematologic Malignancies (MK-4827-001 AM8)

Tesaro, Inc.

Phase 1 Completed
113 enrolled
GenitourinaryGynecologicLymphoidOther hematologic neoplasm

Adnexal Diseases, Endocrine System Diseases, Endocrine Gland Neoplasms, Genital Diseases, Female, Genital Diseases, Male, Genital Neoplasms, Female, Genital Neoplasms, Male, Gonadal Disorders, Neoplasms, Ovarian Diseases, Ovarian Neoplasms, Prostatic Diseases, Prostatic Neoplasms, Urogenital Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic, T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡